Ace Therapeutics, as a company specializing in H. pylori research, offers professional H. pylori vaccine adjuvants discovery services. In terms of H. pylori vaccine adjuvant discovery, we focus on two broad targets, pattern recognition receptors (PRRs) and iNKT cells. And then we select again and collect adjuvants that can be used for mucosal immunization which is considered to be the safest, most convenient, and logical method of immunization against H. pylori infection.
Exploration of PRR agonists as candidate adjuvants for H. pylori vaccines
When a person is infected with H. pylori, it is the PRRs that recognize H. pylori and activate the innate immune response. As a bridge between innate and adaptive immunity, they identify and distinguish between foreign microbial challenges and the damage to self. Targeting different classes of specific PRRs can generate corresponding specific cellular and antibody responses.
Almost all PRRs are potential targets for adjuvants. The most studied adjuvants are agonists of Toll-like receptors (TLRs). For example, adjuvant AS04 and CpG 1018 are agonists of TLRs.
Fig. 1 Pattern recognition receptor-mediated NF-κB signaling (Li & Wu, 2021).
Ace Therapeutics has two ways of screening PRR adjuvants and we particularly focus on the discovery of adjuvants that target PRRs that H. pylori evade. Due to the inherent and effective way that pathogen-associated molecular patterns (PAMPs) activate the immune system, we use innovative chemical, biological and engineering methods to rapidly screen potential PPR adjuvants from naturally occurring pathogenesis-related model molecules and their derivatives. High-throughput screening (HTS) and chemically conjugated synergistic screening are our common screening methods. In addition, based on the ligand scanning technology, we identify potent adjuvant candidates of PPR agonists from peptide and polysaccharide libraries that we collected through homology modeling construction and natural product extraction.
Exploration of iNKT cell agonists as candidate adjuvants for H. pylori vaccines
Invariant natural killer T (iNKT) cells can also act as a link between the innate and adaptive immune systems as they can recognize CD1d-presented glycolipid antigens. iNKT was thought to be a new pathway for CAR-based cancer immunotherapy. It can activate and recruit various antitumor effector cells into the tumor microenvironment to enhance antitumor immune responses. And iNKT has the potential to kill both cancer cells with and without "cancer antigens".
More importantly, a new clinical study found that intranasal administration can more effectively activate iNKT cells in the tumor microenvironment. This provides a valuable direction for the development of therapeutic vaccines for H. pylori-induced gastric cancer.
Ace Therapeutics supports the discovery of a potent H. pylori vaccine adjuvant focused on iNKT cells. We use animal experiments to discover adjuvants that stimulate iNKT cells. Once discovered, these adjuvants will certainly have prospective applications.
Contact us
Two major H. pylori vaccine adjuvant discovery services are supported by Ace Therapeutics. These adjuvant discovery services are based on the natural host immune response stimulated by H. pylori. In addition, mucosal adjuvant discovery for H. pylori is also covered. If you would like to discover H. pylori vaccine adjuvants through the above channels, please contact us and we can provide you with professional services.
References
- Li, D.; Wu, M. Pattern recognition receptors in health and diseases. Signal Transduction and Targeted Therapy. 2021, 6(1): 291.
- Li, Y. Q.; et al. iNKT cell agonists as vaccine adjuvants to combat infectious diseases. Carbohydrate Research. 2022, 513: 108527.
※ All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
